Repeat Chlamydia trachomatis detection frequently occurs within months after C. trachomatis infection treatment. The origins of such infection (persistence versus reinfection from untreated or new partners) are varied and difficult to determine. C. trachomatis strains can be differentiated by sequencing the ompA gene encoding the outer membrane protein A (OmpA). We used OmpA genotyping to investigate the epidemiology of repeat C. trachomatis detection after treatment in C. trachomatis-infected subjects seen at a sexually transmitted diseases clinic. Subjects were enrolled, tested for C. trachomatis, treated with azithromycin, and scheduled for a 6-month follow-up for repeat C. trachomatis testing. OmpA genotyping was performed on C. trachomatis-positive urogenital specimens obtained from patients at enrollment and follow-up. The enrollment visit OmpA genotypes for C. trachomatis were determined for 162 subjects (92% female, 94% African American). C. trachomatis was detected at follow-up in 39 subjects (24%). The OmpA genotype distribution at enrollment did not differ in those with versus those without repeat C. trachomatis detection. Of the 35 subjects with C. trachomatis strains genotyped at enrollment and follow-up, 7 (20%) had the same ompA sequence at both visits, while 28 (80%) had discordant sequences. A new sexual partner was reported more often in subjects with discordant C. trachomatis strains than in those with concordant strains (13 [46%] versus 1 [14%]; P ‫؍‬ 0.195). Half of the subjects with discordant C. trachomatis strains who reported sexual activity since treatment denied a new sexual partner; 62% of these subjects reported that their partner was treated. Our study demonstrates that most repeat C. trachomatis detections after treatment were new infections with a different C. trachomatis strain rather than reinfection with the same strain. OmpA genotyping can be a useful tool in understanding the origins of repeat C. trachomatis detection after treatment.
R
epeat detection of Chlamydia trachomatis within months of an initial chlamydia diagnosis and treatment is common, occurring in up to 20% of patients, or more in some studies (1) (2) (3) . The origins of such repeat C. trachomatis detection (infection persistence versus reinfection from an untreated or new partner) are complex, as are the host and organism characteristics that may predispose humans to have repeat C. trachomatis detection after treatment. C. trachomatis strains can be differentiated by nucleotide sequence analysis of the ompA gene, which encodes an antigenically diverse and abundant outer membrane protein A (OmpA). Of the more than 15 C. trachomatis OmpA genotypes identified, the most common ones isolated from the urogenital tract are genotypes D through K (4) . Within the OmpA genotypes, further nucleotide variation occurs, permitting strain-to-strain variation within isolates of the same C. trachomatis genotype; hence, C. trachomatis strains may be differentiated by their ompA sequence, and there may be different C. trachomatis strains within the same OmpA genotype.
We previously utilized C. trachomatis OmpA genotyping to study the natural history of C. trachomatis infection (spontaneous resolution versus persistence of infection) in the interval between an initial screening and a return for treatment, and we found that the C. trachomatis OmpA genotype J/Ja more often occurred in subjects with spontaneous resolution of C. trachomatis infection prior to treatment and that there were rare instances when subjects had acquired a new C. trachomatis strain (with a different ompA sequence) within this short time interval (5) . We believe that C. trachomatis OmpA genotyping can also be a useful tool for investigating the epidemiology of repeat C. trachomatis detection after treatment, for which only a sparse number of studies have investigated using OmpA serotyping or genotyping (6) (7) (8) (9) . We sought to determine whether the OmpA genotype of the initial infection influenced the risk of repeat C. trachomatis detection and to determine the origins of repeat C. trachomatis detection by evaluating sexual histories and the proportion of subjects with repeat C. trachomatis detection who had concordant versus discordant C. trachomatis strains at enrollment and follow-up visits based on ompA sequencing.
(Data from this study were presented in part as a poster at the 20th International Society for Sexually Transmitted Diseases Research [ISSTDR] Congress, Vienna, Austria, 14 to 17 July 2013.)
MATERIALS AND METHODS
Study subjects and collection of data and specimens. The clinical data (including a sexual history) and urogenital samples were collected during a prospective study of the natural history of C. trachomatis infection from January 2008 through April 2012. The study population comprised HIVnegative male and female patients Ն16 years of age presenting to the Jefferson County Department of Health (JCDH) Sexually Transmitted Diseases (STD) Clinic in Birmingham, Alabama, for the treatment of C. trachomatis infection within 60 days of a positive C. trachomatis screening test. Patients had not been treated at the time of the initial C. trachomatis screening due to the absence of C. trachomatis-associated syndromes (e.g., urethritis or cervicitis) or other treatment indications (e.g., contact with a C. trachomatis-infected partner). At enrollment, the subjects were interviewed, and genital swabs (from the urethra in men and endocervix in women) were tested by a C. trachomatis nucleic acid amplification test (NAAT) (APTIMA Combo 2; Gen-Probe, Inc., San Diego, CA); patients were treated with a single dose of azithromycin (1 g) as directly observed therapy, had a genital swab (and sometimes urine) collected for C. trachomatis OmpA genotyping, and were scheduled for a 6-month follow-up visit for repeat C. trachomatis testing by a NAAT to evaluate for repeat C. trachomatis detection. Our analyses in this report are limited to subjects who returned for follow-up, which in this study was a minimum of 1 month following treatment to limit the possibility of a false-positive NAAT at follow-up due to residual C. trachomatis nucleic acids yet to clear from the genital tract after treatment. We also excluded subjects from this analysis who had a negative C. trachomatis NAAT at enrollment (i.e., spontaneous resolution of the infection prior to treatment), as there would not be a C. trachomatis strain from the enrollment visit to genotype. The study was approved by institutional review boards of the University of Alabama at Birmingham (UAB) and the JCDH.
DNA extraction. C. trachomatis genomic DNA was extracted and purified from 200 l of residual C. trachomatis transport medium containing the genital swab or from urine (1 ml centrifuged at 15,000 ϫ g for 5 min and then resuspended from the pellet in phosphate-buffered saline) using the High Pure PCR template preparation kit (Roche Diagnostics, Mannheim, Germany) following the manufacturer's protocol.
C. trachomatis ompA amplification and sequencing. Nested C. trachomatis ompA amplification was performed using the High-Fidelity PCR master mix kit (Roche Diagnostics, Indianapolis, IN), with primer pairs amplifying a DNA fragment containing the ompA gene from all C. trachomatis OmpA genotypes. Our initial genotyping procedure for this study used the primers and amplification parameters that we previously reported (5). Later, we switched to the PCR primers described by Yang et al. (10) , because these primers increased our yield of successful ompA amplifications. Five microliters of DNA was used with primers Yang 1 (GCCG CTTTGAGTTCTGCTTCCTC) and Yang 2 (ATTTACGTGAGCAGCTC TCTCAT) for the first amplification. Three microliters of the product from this first round was then amplified using primers Yang 3 (TGACTT TGTTTTCGACCGTGTTTT) and Yang 4 (TTTTCTAGATTTCATCTTG TTCAAT/CTG). The amplification conditions for the first round and the nested PCRs were 94°C for 3 min, 40 cycles of 94°C for 30 s, 52°C for 1 min, and 72°C for 1 min, and a final elongation step at 72°C for 10 min. The PCR products were visualized on a 1% agarose gel, purified using the QIAquick PCR purification kit (Qiagen, Inc., Valencia, CA), quantitated by optical density, and sequenced on an ABI automated capillary DNA sequencing system (Applied Biosystems, Foster City, CA) using dye terminator chemistry with the primers that we previously reported (5), but primers Yang 3 and Yang 4 were used for sequencing when the Yang primers had been used for amplification. Sequencing was performed at the Heflin Center Genomics Core Lab at UAB. Sequences were assembled, edited, and compared to chlamydia GenBank sequences for identification.
Statistical analyses. Analyses were conducted with Stata release 8.0 (Stata Corp., College Station, TX). Differences in repeat C. trachomatis detection by demographical characteristics (gender, race, and age) were evaluated by the Pearson chi-square test or the Wilcoxon rank sum test as appropriate. The association of C. trachomatis OmpA distribution from the enrollment visit with the outcome of repeat C. trachomatis detection at follow-up was analyzed using Fisher's exact test. The associations of patient clinical data with the concordance of C. trachomatis strains (i.e., an identical ompA sequence) at the baseline versus follow-up visits or with the discordance of the C. trachomatis strains at these visits was evaluated by parametric (Pearson's chi-square test or Fisher's exact test) or nonparametric (Wilcoxon rank sum test) methods as appropriate. A P value of Յ0.05 was considered statistically significant.
RESULTS
Subject characteristics and C. trachomatis OmpA genotype distribution at enrollment. Of the 180 C. trachomatis-infected subjects with enrollment urogenital specimens available who returned for a follow-up visit, 162 (90%) had C. trachomatis OmpA genotyping successfully performed on the enrollment urogenital specimen. The subject characteristics at enrollment are summarized in Table 1 . Most subjects were female (92%) and African American (94%), with the majority (56%) having prior chlamydia infection documented in the medical record or self-reported. The distribution of C. trachomatis OmpA genotypes in the enrollment visit specimens (in descending order of frequency) was 28% D/Da, 21% E, 17% Ia, 14% F, 11% J/Ja, 7% G, and 2% K (Fig. 1) .
Repeat C. trachomatis detection and relationship to C. trachomatis OmpA genotype distribution at enrollment. The median (range) time to follow-up was 185 days (35 to 365 days). C. trachomatis was detected at follow-up in 39 patients (24%), occurring more commonly in men than women (7 [54%] (Fig. 1) .
Evaluation of origins of repeat C. trachomatis detection through interim sexual history and C. trachomatis ompA amplification and sequencing from enrollment and follow-up urogenital specimens. Of the 39 subjects with repeat C. trachomatis detection at follow-up, 35 (90%) had successful C. trachomatis ompA amplification and sequencing in the enrollment and follow-up urogenital specimens (Fig. 2) . The ompA sequences in the enrollment and follow-up specimens were concordant in 7 patients (20%) and were discordant in 28 (80%). Of the 28 subjects with discordant ompA sequences, 5 (18%) had the same OmpA genotype, illustrating the ability of ompA sequencing to distinguish strains of the same OmpA genotype. There was no significant difference in the median time intervals between the enrollment and follow-up visits for the subjects with concordant versus discordant ompA sequences (175 days versus 184 days; P ϭ 0.74), and concordance did not differ by gender (female, 19%; male, 29%). Sexual activity since treatment at the enrollment visit was reported by 33 (94%) of the 35 subjects with ompA sequencing successfully performed from both visits. The 2 subjects who denied sexual activity since treatment had discordant ompA sequences (one subject with different OmpA genotype Ia strains; the other subject with genotype G at enrollment and genotype D at follow-up), indicating reinfection in these subjects with a new C. trachomatis strain rather than treatment failure. Of the 33 subjects reporting sexual activity since treatment, those infected with a different C. trachomatis strain at follow-up more often reported a new sexual partner since treatment than those with concordant strains (13 [50%] versus 1 [14%]; P ϭ 0.195), but concordance data did not differ by follow-up visit interval or reported partner treatment. The 7 subjects with concordant C. trachomatis strains had all been sexually active since treatment; 6 of the 7 denied a new sexual partner, and 5 of these 6 reported that their partners had been treated, suggesting either possible treatment failure, possible inaccuracy in the reporting of partner treatment, or possible reinfection of their partners from other partners with the same strain, leading to reinfection of the patient. Thirteen of the 26 subjects with discordant C. trachomatis strains who reported sexual activity since treatment denied a new sexual partner; 8 of these 13 (62%) reported that their partners had received treatment, suggesting the possibility that their partners may have had other sexual partners infected with a different C. trachomatis strain and who had not been treated.
DISCUSSION
Our study demonstrated that the majority of STD clinic patients who had repeat C. trachomatis detected at a median follow-up interval of 6 months after treatment were infected with different C. trachomatis strains. These subjects likely either acquired a new C. trachomatis strain from a new partner or acquired one from their original partner who had acquired a new strain from a different partner; the second possibility was further supported by our finding that 13 of the 28 (46%) subjects with discordant strains denied having a new sexual partner and by a previous longitudinal study by Blythe et al., in which female adolescents who reported having only one partner were more likely to have repeat C. trachomatis detection in the first year of follow-up compared with women who had more than one partner after enrollment (6). In our study, there were also 2 subjects with discordant C. trachomatis strains who denied sexual activity since treatment, suggesting that, in some instances, subjects may not have been forthcoming about their sexual activity after treatment. Hence, our study demonstrates how incorporating OmpA genotyping into the investigation of the origins of repeat C. trachomatis infections can be useful in addressing instances of inaccuracy in sexual history.
Two previous studies suggested that the likelihood of having repeat C. trachomatis infection with C. trachomatis strains of the same OmpA serovar/genotype was dependent on the interval of time between the initial and repeat C. trachomatis testing, with concordance of C. trachomatis strains with repeat infection detected more often at early follow-up intervals (Ͻ6 months) after initial infection and discordance of C. trachomatis strains more likely to occur with longer periods of follow-up (Ն6 months) (7, 8) . Batteiger et al. previously reported that, in C. trachomatisinfected subjects seen at an STD clinic who did not have concomitant gonorrhea at their initial visit, the same C. trachomatis OmpA serovar recurrences occurred in 42% in the first 6 months of follow-up versus in only 15% at 6 to 12 months of follow-up (7); it is possible that some of the subjects with concordant serovars actually had infections with different C. trachomatis strains because, in contrast to OmpA genotyping, OmpA serotyping cannot distinguish strains of the same OmpA serovar that have different ompA sequences. In our study, we found that 5 of 12 (42%) subjects in whom we detected the same OmpA genotype at follow-up had a different ompA sequence, confirming that these were new infections with different C. trachomatis strains of the same OmpA genotype. Brunham et al. previously reported that, in a cohort of C. trachomatis-infected sex workers in Nairobi, the same C. trachomatis OmpA genotype recurrences occurred in 62% of the subjects in a follow-up period of 1 to 6 months versus only 11% at Ն6 months of follow-up (8) . Both of these prior studies used C. trachomatis tests of lower sensitivity than that of the C. trachomatis NAAT used in our study, although their high rates of C. trachomatis discordance at 6 months of follow-up (85% to 89%) were highly comparable to the discordance rate in our study (80%), suggesting that the C. trachomatis diagnostic assay used in evaluating the epidemiology of a repeat C. trachomatis infection did not influence the likelihood of repeat infection with concor- dant versus discordant strains. In contrast to the studies mentioned above, Blythe et al. reported that female adolescents with repeat detection of the same C. trachomatis serovar did not have repeat infection detected earlier than those with detection of a different serovar (6) . Finally, in a study evaluating OmpA types in women with C. trachomatis infection detected Ն3 times over Ն2 years, Dean et al. identified a subject with the same ompA sequence in every occurrence; C. trachomatis was detected in many of these occurrences by ligase chain reaction but not by culture, suggesting the possibility that repeat C. trachomatis detection with the same strain in rare instances might represent persistent C. trachomatis infection rather than recurrent infection with the same strain (11) .
Our study also evaluated whether the initial OmpA genotype (at the time of treatment) was associated with a risk for repeat C. trachomatis detection. It is possible that protective immunity against C. trachomatis infection is OmpA type specific and that select OmpA types have differing degrees of immunogenicity. We did not find a significant association of OmpA genotype distribution at enrollment with a risk for repeat C. trachomatis detection, which supports findings previously reported by Batteiger et al., who found no difference in the distribution of genotypes among female adolescents who had a single C. trachomatis infection episode in a longitudinal cohort versus those who had 2 or more infections (9) .
The smaller sample sizes of men and of those with a race/ethnicity other than African American were limitations of our study. The strengths of our study included the use of directly observed single-dose azithromycin for baseline C. trachomatis treatment to avoid treatment nonadherence, the use of a highly sensitive C. trachomatis NAAT for C. trachomatis detection, our high success rate of genotyping the C. trachomatis strains, and our approach of directly comparing the ompA sequences between C. trachomatis strains to help discern whether the strains of the same OmpA genotype were the same or different strains.
In summary, C. trachomatis OmpA genotyping can be a valuable tool in studying the origins of repeat C. trachomatis detection after treatment, which can provide knowledge that is useful for improving C. trachomatis management strategies.
